Close Menu

Eli Lilly

Almac and Lilly will study a predictive marker for use as a companion diagnostic for a combination therapy.

Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.

Nanosphere will develop PGx assays to run on its Verigene SP system.

SeqWright CEO Fei Lu said this week that Lilly is one of an increasing number of pharma customers that have specifically requested sequence capture and sequencing services from the firm.

Under the collaboration, SeqWright, a sequencing service provider based in Houston, will use NimbleGen's sequence capture technology and 454's sequencing platform to selectively enrich and sequence approximately 40 megabases of the human genome.

SeqWright will use the sequencing and sequence capture technologies to identify disease variants.

An Alexandria official would not discuss whether the deal would hasten a decision to begin the project's second phase, which has been delayed due to the ongoing economic upheaval.

Sirius will work with a system of 37 hospitals to test biomarkers for severe sepsis drug response.

The agreement is an extension of an existing deal between the two companies for access to Cerep's GPCR screening portfolio.

Findings from the initiative "could ultimately form the basis for collaboration or licensing agreements between Lilly and external institutions," the company said.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.